Literature DB >> 20106799

High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.

Kristina Hermann Haugaa1, Ida Skrinde Leren, Knut Erik Berge, Jørn Bathen, Jan Pål Loennechen, Ole-Gunnar Anfinsen, Andreas Früh, Thor Edvardsen, Erik Kongsgård, Trond P Leren, Jan P Amlie.   

Abstract

AIM: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited cardiac disease predisposing to life-threatening arrhythmias. We aimed to determine the prevalence of arrhythmias and efficacy of beta-blocker treatment in mutation-positive family members diagnosed by cascade genetic screening. METHODS AND
RESULTS: Relatives of six unrelated CPVT patients were tested for the relevant mutation in the ryanodine receptor-2 gene. Mutation carriers underwent an exercise test at inclusion time and 3 months after the initiation of beta-blocker therapy in the highest tolerable dose. The occurrence of ventricular premature beats, couplets, and non-sustained ventricular arrhythmias (nsVT) were recorded in addition to the heart rate at which they occurred. Thirty family members were mutation carriers and were followed for 22 (13-288) months. Previous undiagnosed CPVT-related symptoms were reported by eight subjects. Exercise test induced ventricular arrhythmias in 23 of the 30 mutation carriers. On beta-blocker treatment, exercise-induced arrhythmias occurred at a lower heart rate (117 +/- 17 vs. 135 +/- 34 beats/min, P = 0.02) but at similar workload (P = 0.78). Beta-blocker treatment suppressed the occurrence of exercise-induced nsVT in three of the four patients, while less severe arrhythmias were unchanged. One patient died during follow-up.
CONCLUSION: Exercise test revealed a high prevalence of arrhythmias in CPVT mutation carriers diagnosed by cascade genetic screening. beta-Blocker therapy appeared to suppress the most severe exercise-induced arrhythmias, while less severe arrhythmias occurred at a lower heart rate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20106799     DOI: 10.1093/europace/eup448

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  16 in total

1.  Sudden death due to catecholaminergic polymorphic ventricular tachycardia following negative stress-test outcome: genetics and clinical implications.

Authors:  Cristian D'Ovidio; Aldo Carnevale; Vincenzo M Grassi; Enrica Rosato; Bernat Del Olmo; Monica Coll; Oscar Campuzano; Anna Iglesias; Ramon Brugada; Antonio Oliva
Journal:  Forensic Sci Med Pathol       Date:  2017-04-13       Impact factor: 2.007

2.  Exercise training prevents ventricular tachycardia in CPVT1 due to reduced CaMKII-dependent arrhythmogenic Ca2+ release.

Authors:  Ravinea Manotheepan; Tore K Danielsen; Mani Sadredini; Mark E Anderson; Cathrine R Carlson; Stephan E Lehnart; Ivar Sjaastad; Mathis K Stokke
Journal:  Cardiovasc Res       Date:  2016-05-08       Impact factor: 10.787

3.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

Review 4.  Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target?

Authors:  Michela Faggioni; Christian van der Werf; Bjorn C Knollmann
Journal:  Trends Cardiovasc Med       Date:  2014-07-10       Impact factor: 6.677

5.  Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.

Authors:  Michela Faggioni; Hyun Seok Hwang; Christian van der Werf; Ineke Nederend; Prince J Kannankeril; Arthur A M Wilde; Björn C Knollmann
Journal:  Circ Res       Date:  2013-01-07       Impact factor: 17.367

6.  Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.

Authors:  Thomas M Roston; Jeffrey M Vinocur; Kathleen R Maginot; Saira Mohammed; Jack C Salerno; Susan P Etheridge; Mitchell Cohen; Robert M Hamilton; Andreas Pflaumer; Ronald J Kanter; James E Potts; Martin J LaPage; Kathryn K Collins; Roman A Gebauer; Joel D Temple; Anjan S Batra; Christopher Erickson; Maria Miszczak-Knecht; Peter Kubuš; Yaniv Bar-Cohen; Michal Kantoch; Vincent C Thomas; Gabriele Hessling; Chris Anderson; Ming-Lon Young; Michel Cabrera Ortega; Yung R Lau; Christopher L Johnsrude; Anne Fournier; Prince J Kannankeril; Shubhayan Sanatani
Journal:  Circ Arrhythm Electrophysiol       Date:  2015-02-24

Review 7.  Arrhythmogenesis of Sports: Myth or Reality?

Authors:  Saad Fyyaz; Michael Papadakis
Journal:  Arrhythm Electrophysiol Rev       Date:  2022-04

8.  [Catecholaminergic polymorphic ventricular tachycardia].

Authors:  G Frommeyer; C Pott; E Schulze-Bahr; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09-18

9.  Follow-up with exercise test of effort-induced ventricular arrhythmias linked to ryanodine receptor type 2 gene mutations.

Authors:  Alexandros Klavdios Steriotis; Andrea Nava; Alessandra Rampazzo; Cristina Basso; Gaetano Thiene; Luciano Daliento; Antonio Franco Folino; Ilaria Rigato; Elisa Mazzotti; Giorgia Beffagna; Elisa Carturan; Domenico Corrado; Barbara Bauce
Journal:  Am J Cardiol       Date:  2012-01-03       Impact factor: 2.778

10.  CPVT-associated cardiac ryanodine receptor mutation G357S with reduced penetrance impairs Ca2+ release termination and diminishes protein expression.

Authors:  Yingjie Liu; Jinhong Wei; Siobhan M Wong King Yuen; Bo Sun; Yijun Tang; Ruiwu Wang; Filip Van Petegem; S R Wayne Chen
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.